Issued by Citigate Dewe Rogerson Ltd, Birmingham
Date: Wednesday, 7 July 2010
Dechra® Pharmaceuticals PLC
("Dechra" or "The Group")
Trading Update
The Board of Dechra issues the following update ahead of the publication of the Group's Preliminary Results for the year ended 30 June 2010 which will be announced on Tuesday 7 September 2010.
Group revenue for the year ended 30 June 2010 was approximately 5.3% ahead of the equivalent period last year.
European Pharmaceuticals
Revenue from this division increased by approximately 9.0% compared to last year with both specialist pet diets and pharmaceuticals showing solid growth. Foreign currency fluctuations did not have a material impact on these numbers.
Our manufacturing business, Dales® Pharmaceuticals, performed well during the period due to improved efficiency and increased production of both our own and third party products.
US Pharmaceuticals
Overall revenue was approximately 36.6% higher than last year. Revenue from US Vetoryl® in the period was US$6.6 million.
Services
This division revenue grew by approximately 3.3% compared to last year.
Balance Sheet
Operating cash flow during the period was strong, resulting in a further reduction in net borrowings.
Summary
Although our markets have experienced slower rates of growth than historical levels, we have demonstrated solid progress compared to last year. The Group continues to perform robustly and in line with management expectations; we remain confident about our future growth prospects.
Enquiries: |
|
Ian Page, Chief Executive |
Fiona Tooley, Director |
Simon Evans, Group Finance Director |
Keith Gabriel, Senior Account Manager |
Dechra Pharmaceuticals PLC |
Citigate Dewe Rogerson |
Telephone: + 44 (0) 1782 771100 |
Telephone: +44 (0) 121 362 4035 |
Mobile: +44 (0) 777 5642222 (IP) |
Mobile: +44 (0) 778 570 3523 (FT) |
Mobile: +44 (0) 777 5642220 (SE) |
|
Ticker: Full Listing (Pharmaceuticals): DPH |
Trademarks appear throughout this release in italics. Dechra and the Dechra 'D' logo are registered Trademarks of Dechra Pharmaceuticals PLC.